Literature DB >> 25918035

Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens.

Israel D R Salazar1, Maribel Merino López2, Jessica Chang2, Philip F Halloran3.   

Abstract

Intimal arteritis (the presence of v-lesions) in kidney transplant biopsy specimens is believed to have major prognostic and diagnostic significance. We assessed the relationship of v-lesions to prognosis in 703 indication biopsy specimens and used microarray-based molecular tests to re-examine the relationship of v-lesions to rejection. v-Lesions were noted in 49 specimens (7%) and were usually mild (v1). The presence of v-lesions had no effect on graft survival compared with the absence of v-lesions. Pathologists using current conventions almost always interpreted v-lesions as reflecting T cell-mediated rejection (TCMR), either pure or mixed with antibody-mediated rejection (ABMR). The molecular scores questioned the conventional diagnoses in 29 of 49 specimens (59%), including ten that were conventional TCMR with no molecular rejection and nine that were conventional TCMR mixed with pure ABMR molecularly. The presence of tubulointerstitial inflammation (i-t) meeting TCMR criteria allowed subclassification of v-lesion specimens into 21 i-t-v-lesion specimens and 28 isolated v-lesion specimens. Molecular TCMR scores were positive in 95% of i-t-v-lesion specimens but only 21% of isolated v-lesion specimens. Molecular ABMR scores were often positive in isolated v-lesion biopsies (46%). Time of biopsy after transplantation was critical for understanding isolated v-lesions: most early isolated v-lesion specimens had no molecular rejection and were DSA negative, whereas most isolated >1 year after transplantation had positive DSA and ABMR scores. Therefore, v-lesions in indication biopsy specimens do not affect prognosis and can reflect TCMR, ABMR, or no rejection. Time after transplantation, DSA, and accompanying inflammation provide probabilistic basis for interpreting v-lesions.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  kidney; kidney biopsy; kidney transplantation

Mesh:

Substances:

Year:  2015        PMID: 25918035      PMCID: PMC4657840          DOI: 10.1681/ASN.2014111064

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  40 in total

1.  Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

Authors:  J Sellarés; D G de Freitas; M Mengel; J Reeve; G Einecke; B Sis; L G Hidalgo; K Famulski; A Matas; P F Halloran
Journal:  Am J Transplant       Date:  2011-11-14       Impact factor: 8.086

Review 2.  Acute vascular rejection after renal transplantation and isolated v-lesion.

Authors:  Tomokazu Shimizu; Tatsu Tanabe; Hiroki Shirakawa; Kazuya Omoto; Hideki Ishida; Kazunari Tanabe
Journal:  Clin Transplant       Date:  2012-07       Impact factor: 2.863

Review 3.  Current status of immunosuppressive agents for solid organ transplantation in children.

Authors:  Tracy Coelho; Michael Tredger; Anil Dhawan
Journal:  Pediatr Transplant       Date:  2012-03

4.  Antibody-mediated vascular rejection: relation to causation.

Authors:  Brian J Nankivell
Journal:  Lancet       Date:  2012-11-23       Impact factor: 79.321

5.  Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.

Authors:  J Reeve; J Sellarés; M Mengel; B Sis; A Skene; L Hidalgo; D G de Freitas; K S Famulski; P F Halloran
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

Review 6.  Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum.

Authors:  Mark Haas
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

7.  Clinicopathological analysis of acute vascular rejection cases after renal transplantation.

Authors:  Tomokazu Shimizu; Hideki Ishida; Hiroki Shirakawa; Kazuya Omoto; Kuniko Tsunoyama; Tadahiko Tokumoto; Kazunari Tanabe
Journal:  Clin Transplant       Date:  2010-07       Impact factor: 2.863

8.  Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases.

Authors:  J Sellarés; D G de Freitas; M Mengel; B Sis; L G Hidalgo; A J Matas; B Kaplan; P F Halloran
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

9.  Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.

Authors:  B Sis; M Mengel; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; W M Baldwin; E R Bracamonte; V Broecker; F Cosio; A J Demetris; C Drachenberg; G Einecke; J Gloor; D Glotz; E Kraus; C Legendre; H Liapis; R B Mannon; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; E R Rodriguez; D Seron; S Seshan; M Suthanthiran; B A Wasowska; A Zachary; A Zeevi
Journal:  Am J Transplant       Date:  2010-01-29       Impact factor: 8.086

10.  Antibody-mediated vascular rejection of kidney allografts: a population-based study.

Authors:  Carmen Lefaucheur; Alexandre Loupy; Dewi Vernerey; Jean-Paul Duong-Van-Huyen; Caroline Suberbielle; Dany Anglicheau; Jérôme Vérine; Thibaut Beuscart; Dominique Nochy; Patrick Bruneval; Dominique Charron; Michel Delahousse; Jean-Philippe Empana; Gary S Hill; Denis Glotz; Christophe Legendre; Xavier Jouven
Journal:  Lancet       Date:  2012-11-23       Impact factor: 79.321

View more
  10 in total

1.  Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.

Authors:  Jeff Reeve; Georg A Böhmig; Farsad Eskandary; Gunilla Einecke; Carmen Lefaucheur; Alexandre Loupy; Philip F Halloran
Journal:  JCI Insight       Date:  2017-06-15

Review 2.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

3.  The Clinical and Pathologic Phenotype of Antibody-Mediated Vascular Rejection Diagnosed Using Arterial C4d Immunoperoxidase.

Authors:  Brian J Nankivell; Meena Shingde; Chow H P'Ng; Ankit Sharma
Journal:  Kidney Int Rep       Date:  2022-05-05

Review 4.  Molecular assessment of disease states in kidney transplant biopsy samples.

Authors:  Philip F Halloran; Konrad S Famulski; Jeff Reeve
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

5.  Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis.

Authors:  Caroline Wehmeier; Patrizia Amico; Patricia Hirt-Minkowski; Argyrios Georgalis; Gideon Höenger; Thomas Menter; Michael Mihatsch; Felix Burkhalter; Juerg Steiger; Michael Dickenmann; Helmut Hopfer; Stefan Schaub
Journal:  Transplant Direct       Date:  2017-02-09

6.  Isolated Vascular Lesions (IVL) in Early Allograft Biopsies: A Case Series.

Authors:  Vennela Bangaru; Megha Uppin; Manjusha Yadla; Swarnalatha Gudithi; Gangadhar Taduri; SreeBhushan Raju
Journal:  Indian J Nephrol       Date:  2019 Sep-Oct

7.  Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss.

Authors:  Vojtech Petr; Petra Hruba; Marek Kollar; Karel Krejci; Roman Safranek; Sona Stepankova; Jarmila Dedochova; Jana Machova; Jakub Zieg; Janka Slatinska; Eva Pokorna; Ondrej Viklicky
Journal:  Transplant Direct       Date:  2021-10-22

8.  Early Posttransplant Isolated v1 Lesion Does Not Need to Be Treated and Does Not Lead to Increased Fibrosis.

Authors:  Irfan Moinuddin; Bijin Thajudeen; Amy Sussman; Machaiah Madhrira; Erika Bracamonte; Mordecai Popovtzer; Pradeep V Kadambi
Journal:  Case Rep Transplant       Date:  2016-05-17

9.  Early isolated V-lesion may not truly represent rejection of the kidney allograft.

Authors:  Mariana Wohlfahrtova; Petra Hruba; Jiri Klema; Marek Novotny; Zdenek Krejcik; Viktor Stranecky; Eva Honsova; Petra Vichova; Ondrej Viklicky
Journal:  Clin Sci (Lond)       Date:  2018-10-29       Impact factor: 6.124

10.  Intimal Arteritis and Microvascular Inflammation Are Associated With Inferior Kidney Graft Outcome, Regardless of Donor-Specific Antibodies.

Authors:  Marek Novotny; Petra Hruba; Martin Kment; Ludek Voska; Katerina Kabrtova; Antonij Slavcev; Ondrej Viklicky
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.